ACAD Intrinsic Valuation and Fundamental Analysis - ACADIA Pharmaceuticals Inc - Alpha Spread

ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.42 USD 0.55% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one ACAD stock under the Base Case scenario is 22.54 USD. Compared to the current market price of 16.42 USD, ACADIA Pharmaceuticals Inc is Undervalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACAD Intrinsic Value
22.54 USD
Undervaluation 27%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ACADIA Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ACAD based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about ACAD?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about ACADIA Pharmaceuticals Inc

Provide an overview of the primary business activities
of ACADIA Pharmaceuticals Inc.

What unique competitive advantages
does ACADIA Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does ACADIA Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in ACADIA Pharmaceuticals Inc recently?

Summarize the latest earnings call
of ACADIA Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ACADIA Pharmaceuticals Inc.

Provide P/S
for ACADIA Pharmaceuticals Inc.

Provide P/E
for ACADIA Pharmaceuticals Inc.

Provide P/OCF
for ACADIA Pharmaceuticals Inc.

Provide P/FCFE
for ACADIA Pharmaceuticals Inc.

Provide P/B
for ACADIA Pharmaceuticals Inc.

Provide EV/S
for ACADIA Pharmaceuticals Inc.

Provide EV/GP
for ACADIA Pharmaceuticals Inc.

Provide EV/EBITDA
for ACADIA Pharmaceuticals Inc.

Provide EV/EBIT
for ACADIA Pharmaceuticals Inc.

Provide EV/OCF
for ACADIA Pharmaceuticals Inc.

Provide EV/FCFF
for ACADIA Pharmaceuticals Inc.

Provide EV/IC
for ACADIA Pharmaceuticals Inc.

Show me price targets
for ACADIA Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for ACADIA Pharmaceuticals Inc?

What are the Net Income projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for ACADIA Pharmaceuticals Inc?

What are the EPS projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past EPS estimates
for ACADIA Pharmaceuticals Inc?

What are the EBIT projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for ACADIA Pharmaceuticals Inc?

Compare the revenue forecasts
for ACADIA Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ACADIA Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ACADIA Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of ACADIA Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of ACADIA Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing ACADIA Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of ACADIA Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for ACADIA Pharmaceuticals Inc.

Provide ROE
for ACADIA Pharmaceuticals Inc.

Provide ROA
for ACADIA Pharmaceuticals Inc.

Provide ROIC
for ACADIA Pharmaceuticals Inc.

Provide ROCE
for ACADIA Pharmaceuticals Inc.

Provide Gross Margin
for ACADIA Pharmaceuticals Inc.

Provide Operating Margin
for ACADIA Pharmaceuticals Inc.

Provide Net Margin
for ACADIA Pharmaceuticals Inc.

Provide FCF Margin
for ACADIA Pharmaceuticals Inc.

Show all solvency ratios
for ACADIA Pharmaceuticals Inc.

Provide D/E Ratio
for ACADIA Pharmaceuticals Inc.

Provide D/A Ratio
for ACADIA Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for ACADIA Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for ACADIA Pharmaceuticals Inc.

Provide Quick Ratio
for ACADIA Pharmaceuticals Inc.

Provide Current Ratio
for ACADIA Pharmaceuticals Inc.

Provide Cash Ratio
for ACADIA Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for ACADIA Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for ACADIA Pharmaceuticals Inc?

What is the current Free Cash Flow
of ACADIA Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for ACADIA Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ACADIA Pharmaceuticals Inc

Current Assets 728.9m
Cash & Short-Term Investments 500.9m
Receivables 110.4m
Other Current Assets 117.6m
Non-Current Assets 185.2m
PP&E 56.5m
Intangibles 107.9m
Other Non-Current Assets 20.8m
Current Liabilities 337.9m
Accounts Payable 19.9m
Accrued Liabilities 318m
Non-Current Liabilities 59.5m
Other Non-Current Liabilities 59.5m
Efficiency

Earnings Waterfall
ACADIA Pharmaceuticals Inc

Revenue
890.5m USD
Cost of Revenue
-73.7m USD
Gross Profit
816.9m USD
Operating Expenses
-794.1m USD
Operating Income
22.8m USD
Other Expenses
7.8m USD
Net Income
30.5m USD

Free Cash Flow Analysis
ACADIA Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Acadia Pharmaceuticals reported $242 million in Q2 revenues, driven by its key drugs NUPLAZID and DAYBUE. NUPLAZID sales grew 11% year-over-year, prompting an increased 2024 revenue guidance to $590-$610 million. DAYBUE, however, saw a slowdown in new patient starts, leading to a revised guidance of $340-$370 million. Despite this, DAYBUE's active patients grew to 900, bouncing back from a Q1 dip. Acadia remains optimistic with over $500 million in cash and no debt, poised to invest in its Alzheimer's and Prader-Willi syndrome pipelines for future growth.

What is Earnings Call?
Fundamental Scores

ACAD Profitability Score
Profitability Due Diligence

ACADIA Pharmaceuticals Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
38/100
Profitability
Score

ACADIA Pharmaceuticals Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

ACAD Solvency Score
Solvency Due Diligence

ACADIA Pharmaceuticals Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

ACADIA Pharmaceuticals Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACAD Price Targets Summary
ACADIA Pharmaceuticals Inc

Wall Street analysts forecast ACAD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACAD is 25.78 USD with a low forecast of 12.12 USD and a high forecast of 40.95 USD.

Lowest
Price Target
12.12 USD
26% Downside
Average
Price Target
25.78 USD
57% Upside
Highest
Price Target
40.95 USD
149% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ACAD?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for ACAD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about ACAD dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

ACAD Price
ACADIA Pharmaceuticals Inc

1M 1M
+5%
6M 6M
-12%
1Y 1Y
-31%
3Y 3Y
-2%
5Y 5Y
-60%
10Y 10Y
-37%
Annual Price Range
16.42
52w Low
14.62
52w High
31.77
Price Metrics
Average Annual Return -14.39%
Standard Deviation of Annual Returns 36.4%
Max Drawdown -77%
Shares Statistics
Market Capitalization 2.7B USD
Shares Outstanding 166 623 000
Percentage of Shares Shorted 9.28%

Competitive Landscape

Ownership

ACAD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ACAD News

Other Videos

Profile

ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.7B USD

Dividend Yield

0%

Description

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Contact

CALIFORNIA
San Diego
3611 Valley Centre Dr Ste 300
+18585582871.0
www.acadia-pharm.com

IPO

2004-05-27

Employees

514

Officers

See Also

Discover More
What is the Intrinsic Value of one ACAD stock?

The intrinsic value of one ACAD stock under the Base Case scenario is 22.54 USD.

Is ACAD stock undervalued or overvalued?

Compared to the current market price of 16.42 USD, ACADIA Pharmaceuticals Inc is Undervalued by 27%.

Back to Top